Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.
about
Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overviewCrohn's disease and skinA study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels.Etanercept-induced pityriasis lichenoides chronica in a patient with rheumatoid arthritis.Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo.Autopsy-proven demyelination associated with infliximab treatmentHenoch-Schönlein Purpura with Adalimumab Therapy for Ulcerative Colitis: A Case Report and Review of the Literature.Safety profile of biological therapies for treating rheumatoid arthritis.The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents.Patient reports of the frequency and severity of adverse reactions associated with biological agents prescribed for psoriasis in Brazil.Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.Fcγ receptor 3B polymorphism is associated with hypersensitivity reactions to adalimumab in Japanese patients with rheumatoid arthritis.The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review
P2860
Q26738918-34C202B2-8DEA-42F8-9971-B6D51A76AD9EQ26752869-9956B162-89AC-4045-B38A-0957785C42F5Q35100143-2649373E-EF80-478F-BEAA-44DC2C3B4960Q35144172-DCBB7A5D-B458-4594-BA09-72658E3518F7Q36094915-EF074786-0DC5-4FC9-811D-36A37BE78DB0Q36562584-5835C813-58EE-4187-A9B5-302E5CE46162Q37162850-8D2DD003-164E-4284-9835-BB3A27101573Q38665700-45997DC7-7C8F-42C8-A401-CC277FA0AE8DQ38755133-737CF233-43A7-4518-93CB-CF569BB3B11BQ39361308-B6B916FE-4C29-456C-B0B6-E56148A334C0Q44365951-73D53602-D9E1-4B79-BE37-BF8E7469B3B7Q51026740-6B7546CF-DE5B-4894-8FBD-CA752754A140Q54145042-D240E507-AEAD-4188-8188-A54C849F6B8EQ58773859-BAAF3BD9-6811-482D-A8EA-9CC206A4DBC9
P2860
Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Cutaneous adverse events durin ...... erapies in rheumatic diseases.
@en
Cutaneous adverse events durin ...... erapies in rheumatic diseases.
@nl
type
label
Cutaneous adverse events durin ...... erapies in rheumatic diseases.
@en
Cutaneous adverse events durin ...... erapies in rheumatic diseases.
@nl
prefLabel
Cutaneous adverse events durin ...... erapies in rheumatic diseases.
@en
Cutaneous adverse events durin ...... erapies in rheumatic diseases.
@nl
P2093
P2860
P50
P356
P1476
Cutaneous adverse events durin ...... herapies in rheumatic diseases
@en
P2093
BIOBADASER 2.0 Study Group
Juan J Gomez-Reino
Mercè Alsina
P2860
P304
P356
10.1002/ACR.22096
P577
2013-12-01T00:00:00Z